1Attal N. Cruccu G. Baron H. el al. Eur J N.urol. EFNS guide- lines on Ihe pharmac'logical treatment of neuropalhi' pain: 2010 revision[J]. Eur J N,-'urol. 2010. 17(9): 1113-1188.
2Dworkin RIt. O'Connor AB. Backonja M. el al. Pharmalogivlnalltlgenlenl of Iletlropalhic pain:evidence-based recommend-a- tions[J]. Pain. 2007. 132(3): 237-251.
3Odora RB. Jams WD, Berger TG. Andrews' Diseases of the Skiu [M]. 9th ed. Beijing: Svience Press. 2001: 473-476.
4Dworkin RH,Perkins FM,Nagasako EM. et al. Drospects for the Clin J Pain, 2000. 16(2 Suppl): S90-100.
5Christo PJ, Hobelmann G. Maine DN. IMsl-herpelie neuralgia in older aduhs:evidetce-based approaches to ulinical manmagement [J]. Dntgs Aging. 2007. 24( 1): 1-1 9.
6Kost RG, Straus SE. Posthtrpeliv neuralgia-ialhogensis treatment and prevention[J]. N Engl J Mcd. 1996. 33.5(1): 32-42.
7Liesegang TJ. Varicell zoster viral disease [J].Mayo Clin Proc. 1999. 74(10): 993-998.
8Taylor CP. Angelotti T. Fauman E. pharmacology' and mechanism of at:lion of pregabalin: The calcittm charnnel α2-δ(alpha 2-d- lat) subunil as a target for antiepileptic drug discovery [J]. Epilepsy RES, 2007. 73(2): 1372-1501.
